Assurance in clinical trial design

被引:199
|
作者
O'Hagan, A
Stevens, JW
Campbell, MJ
机构
[1] Univ Sheffield, Ctr Bayesian Stat Hlth Econ, Sheffield S3 7RH, S Yorkshire, England
[2] AstraZeneca R&D Charnwood, Loughborough, Leics, England
[3] Univ Sheffield, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England
关键词
assurance; Bayesian analysis; Bayesian clinical trial simulation; binary data; design of experiments; expected power; power; preposterior analysis; prior distribution; sample size;
D O I
10.1002/pst.175
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Conventional clinical trial design involves considerations of power, and sample size is typically chosen to achieve a desired power conditional on a specified treatment effect. In practice, there is considerable uncertainty about what the true underlying treatment effect may be, and so power does not give a good indication of the probability that the trial will demonstrate a positive outcome. Assurance is the unconditional probability that the trial will yield a 'positive outcome'. A positive outcome usually means a statistically significant result, according to some standard frequentist significance test. The assurance is then the prior expectation of the power, averaged over the prior distribution for the unknown true treatment effect. We argue that assurance is an important measure of the practical utility of a proposed trial, and indeed that it will often be appropriate to choose the size of the sample (and perhaps other aspects of the design) to achieve a desired assurance, rather than to achieve a desired power conditional on an assumed treatment effect. We extend the theory of assurance to two-sided testing and equivalence trials. We also show that assurance is straightforward to compute in some simple problems of normal, binary and gamma distributed data, and that the method is not restricted to simple conjugate prior distributions for parameters. Several illustrations are given. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:187 / 201
页数:15
相关论文
共 50 条
  • [1] Statistical Power and Bayesian Assurance in Clinical Trial Design
    Chen, Ding-Geng
    Chen, Jenny K.
    [J]. NEW FRONTIERS OF BIOSTATISTICS AND BIOINFORMATICS, 2018, : 193 - 200
  • [2] Assurance in vaccine efficacy clinical trial design based on immunological responses
    Callegaro, Andrea
    Zahaf, Toufik
    Tibaldi, Fabian
    [J]. BIOMETRICAL JOURNAL, 2021, 63 (07) : 1434 - 1443
  • [3] Assurance for clinical trial design with normally distributed outcomes: Eliciting uncertainty about variances
    Alhussain, Ziyad A.
    Oakley, Jeremy E.
    [J]. PHARMACEUTICAL STATISTICS, 2020, 19 (06) : 827 - 839
  • [4] Quality assurance metrics in clinical trial conduct
    Li, Jennifer
    Sellmann, Susanna
    Philip, Lindsay
    Guglielmi, Cristina
    Degendorfer, Pamela
    Oza, Amit M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07)
  • [5] QUALITY ASSURANCE IN THE CHART CLINICAL-TRIAL
    AIRD, EGA
    WILLIAMS, C
    MOTT, GTM
    DISCHE, S
    SAUNDERS, MI
    [J]. RADIOTHERAPY AND ONCOLOGY, 1995, 36 (03) : 235 - 244
  • [6] Process maps in clinical trial quality assurance
    Rosen, Daniel H.
    Johnson, Sandra
    Kebaabetswe, Poloko
    Thigpen, Michael
    Smith, Dawn K.
    [J]. CLINICAL TRIALS, 2009, 6 (04) : 373 - 377
  • [7] From statistical power to statistical assurance: It's time for a paradigm change in clinical trial design
    Chen, Ding-Geng
    Ho, Shuyen
    [J]. COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 2017, 46 (10) : 7957 - 7971
  • [9] The Clinical Trial Design
    Naqvi, Haider A.
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2014, 24 (04): : 221 - 223
  • [10] Quality assurance for clinical dosimetry of the European trial on BNCT in Petten
    Rassow, J
    Stecher-Rasmussen, F
    Appelman, K
    Garbe, S
    Morrissey, J
    Moss, R
    Ravensberg, K
    de Melin, FR
    Sauerwein, W
    Vroegindeweij, C
    Watkins, R
    [J]. FRONTIERS IN NEUTRON CAPTURE THERAPY, VOLS 1 AND 2, 2001, : 161 - 171